Quest (Celera) has noted that there is growing support for a...

Quest (Celera) has noted that there is growing support for a lung cancer screening
program in the USA with recommendation from the US Preventative Screening Task
Force (December 2013). Their estimate for the target market of the test is 7 million
people annually, who are at high risk for lung cancer.

Quest (Celera) has until 31 October 2014 to commercialise their lung cancer blood
test with MK included, after which they maintain their ability to use MK, but will lose
exclusivity under the terms of the license agreement.